Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

IAC/InteractiveCorp Stock Will Shake off This Dip Nicely

By Chris Lau, InvestorPlace Contributor

Despite the fact that IAC stock is close to yearly highs, the company continues to trade at a big discount to fair value. That may change as investors take notice to its future prospects.

Video-Centric Content Has Momo Inc (ADR) Stock on the Mend

By Chris Lau, InvestorPlace Contributor

Momo is pushing multiple social tools that encourage online chat, adding video-centric content to fuel user growth. MOMO stock is on the mend

Is Gilead Sciences, Inc. Stock Still a Solid Value Play?

By Chris Lau, InvestorPlace Contributor

Despite a weak fourth-quarter, Gilead Sciences (GILD) stock still has deep value. If its drug studies play out, it could return to growth sooner than expected.

Why Qualcomm, Inc. Stock Won’t Trade Over $80 Anytime Soon

By Chris Lau, InvestorPlace Contributor

Qualcomm is trading well below the offer price made by Broadcom and is in a royalty payment dispute with Apple. For now, QCOM stock will trade at a discount.

A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent

By Chris Lau, InvestorPlace Contributor

The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon -- not from the renewed interest in biotech stocks but because of Aurina’s upcoming…

Helios and Matheson Analytics Inc May Win With MoviePass

By Chris Lau, InvestorPlace Contributor

Something should not sit right with investors when a company hints at blockchain technology getting incorporated into its business model. But when Helios and Matheson…

Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits

By Chris Lau, InvestorPlace Contributor

VRX stock has soared in recent months as investors expect Valeant to continue improving its business in 2018.

Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally

By Chris Lau, InvestorPlace Contributor

Marijuana stock investing is fraught with risks, after the big run-up recently. Scrutinize the earnings potential for these companies first.

Bet Against Synergy Pharmaceuticals Inc Stock Has Paid off — for Now

By Chris Lau, InvestorPlace Contributor

SGYP stock's under-performance is due to Trulance sales not ramping up fast enough and that could change in the very near future.

Facebook, Inc. Still Pledging to Become a Better Social Destination

By Chris Lau, InvestorPlace Contributor

Facebook stock is hovering at new highs and more growth is on the way as management re-invents the site to better serve its users.

Load More